Bank Of New York Mellon Corp Annovis Bio, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$12.33 - $22.1 $421,969 - $756,328	34,223 New	34,223 $527 Million
Q4 2022 Feb 14, 2023	BUY	$10.99 - $13.55 $376,110 - $463,721	34,223 New	34,223 $459,000
Q3 2022 Nov 14, 2022	BUY	$10.26 - $21.81 $90,667 - $192,734	8,837 Added 34.67%	34,329 $470,000
Q2 2022 Aug 15, 2022	SELL	$8.61 - $13.87 $284 - $457	-33 Reduced 0.13%	25,492 $289,000
Q1 2022 May 11, 2022	SELL	$11.84 - $19.78 $63,675 - $106,376	-5,378 Reduced 17.4%	25,525 $340,000

Q4 2021 Feb 11, 2022	BUY	$17.58 - $37.67 $85,561 - $183,339	4,867 Added 18.69%	30,903 $543,000
Q3 2021 Nov 12, 2021	BUY	$30.95 - $120.97 $119,714 - $467,911	3,868 Added 17.45%	26,036 $826,000
Q2 2021 Aug 11, 2021	BUY	$21.55 - $96.1 $477,720 - $2.13 Million	22,168 New	22,168 $1.9 Million

1.2M

779K

1.77M

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $45.4M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.